21 Aug 2025 by admin in UncategorizedComments Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
08 Jul 2025 by admin in UncategorizedComments U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer
08 Jul 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
30 Jun 2025 by admin in UncategorizedComments Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
26 Jun 2025 by admin in UncategorizedComments Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
16 Jun 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
11 Jun 2025 by admin in UncategorizedComments Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
21 Apr 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
17 Apr 2025 by admin in UncategorizedComments Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
17 Apr 2025 by admin in UncategorizedComments Adicet Bio Appoints Michael Grissinger to the Board of Directors
07 Apr 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Haley Laken, Ph.D., as Chief Scientific Oficer April 7, 2025
07 Apr 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Laura Sepp-Lorenzino, Ph.D., to Its Board of Directors
20 Mar 2025 by admin in UncategorizedComments Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
17 Mar 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Oficer and Chief Medical Officer
07 Jan 2025 by admin in UncategorizedComments Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
07 Jan 2025 by admin in UncategorizedComments Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
07 Jan 2025 by admin in UncategorizedComments Alebund Pharmaceutical announced the first closing of RMB 550 million in Series C financing
06 Jan 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
06 Jan 2025 by admin in UncategorizedComments Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
19 Dec 2024 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
18 Dec 2024 by admin in UncategorizedComments Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
10 Dec 2024 by admin in UncategorizedComments NextCure Announces Acceptance of IND Application for LNCB74
26 Nov 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 Nov 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
20 Nov 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
19 Nov 2024 by admin in UncategorizedComments Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
18 Nov 2024 by admin in UncategorizedComments Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
12 Nov 2024 by admin in UncategorizedComments Zenas BioPharma Completes Targeted Enrolment of the Phase 3 INDIGO Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) in Immunoglobulin G4-Related Disease (IgG4-RD)
12 Nov 2024 by admin in UncategorizedComments Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10 Nov 2024 by admin in UncategorizedComments Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
23 Oct 2024 by admin in UncategorizedComments Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
16 Oct 2024 by admin in UncategorizedComments Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
30 Sep 2024 by admin in UncategorizedComments Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
18 Sep 2024 by admin in UncategorizedComments Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
12 Sep 2024 by admin in UncategorizedComments Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
10 Sep 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
03 Sep 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
